Luis Antonio Marques da Costa (041E-4ADE-FB64)

Curriculum Vitae

L. Costa’s interests in clinical research have been focus in the area of bone metastases (BM) since 1995. In a cooperative project between the Hospital de Santa Maria in Lisbon and Dr. Allan Lipton Lab at the Penn State University, USA, clinical value of type I bone collagen fragments to monitor treatment response in patients with BM was tested, showing that these are useful biochemical biomarkers of response in clinical trials testing new drugs to treat BM. L. Costa’s research group also disclosed the role of matrix metalloproteinases (MMPs) in osteoclast independent mechanisms of bone degradation, and are particularly interested in testing the role of MMP-1-derived collagen fragments as growth/survival factors for cancer cells. Over the years, L. Costa has been collaborating with Prof. Rakesh Kumar, former chairman of Department of Molecular & Cellular Oncology at M. D. Anderson Cancer Center, USA, in research projects focusing in breast cancer. The cooperative efforts led to the identification of the correlation between lymph node metastases and the expression of paxillin in tumors. Ongoing projects focus on triple negative breast cancer and synchronous bilateral breast cancer, as part of the Global Cancer Genomics Consortium activities. At IMM, projects ongoing aim to understand the relationship between estrogen dependence and cancer cell tropism to bone; and the role of phospholipase C family in colorectal cancer progression. Furthermore, an extensive analysis denominated oncodynamics is on going, in which liquid biopsies of breast, prostate, colorectal and melanoma cancers are being collected and different indicators are being measured such as presence of circulating tumor cells and exosomes, analysis of circulating tumor DNA and of the immune profile. In the Oncology Division at Hospital de Santa Maria L. Costa is deeply involved in clinical research. In the last two years L. Costa was the PI in 17 clinical trials in breast cancer and bone metastases.

Ler resumo completo ↓

Identificação

Identificação pessoal

Nome completo: Luis Antonio Marques da Costa

Nomes de citação

Costa, Luis

Identificadores de autor

Ciência ID: 041E-4ADE-FB64
ORCID iD: 0000-0002-4782-7318

Telefones

Fax

(+351) 217805615 (Profissional)

Telefone

(+351 ) 217805096 (Profissional)

Moradas

Serviço de Oncologia do Hospital de Santa Maria, Piso 3, 1649-035 , Lisboa, Lisboa, Portugal (Profissional)

Domínios de atuação

Ciências Médicas e da Saúde - Medicina Clínica - Oncologia

Idiomas

Idioma	Conversação	Leitura	Escrita	Compreensão	Peer-review
Português (Idioma materno)
Inglês	Utilizador proficiente (C2)	Utilizador proficiente (C2)	Utilizador proficiente (C2)	Utilizador proficiente (C2)	Utilizador proficiente (C2)

Formação

	Grau	Classificação
2002 Concluído	Medical oncology (Doutoramento) Universidade de Lisboa Faculdade de Medicina, Portugal
1985 Concluído	Medicina (Licenciatura) Universidade de Lisboa Faculdade de Medicina, Portugal

Percurso profissional

Docência no Ensino Superior

	Categoria Profissional Instituição de acolhimento	Empregador
2016 - 2019	Professor Associado Convidado (Docente Universitário)	Universidade de Lisboa, Portugal

2016 - 2018	Professor Associado Convidado (Docente Universitário)	Universidade de Lisboa, Portugal

2014 - 2016	Professor Associado (Docente Universitário)	Universidade de Lisboa Faculdade de Medicina, Portugal

2014 - 2016	Professor Associado (Docente Universitário)	Universidade de Lisboa Faculdade de Medicina, Portugal

2013 - 2014	Professor Auxiliar (Docente Universitário)	Universidade de Lisboa Faculdade de Medicina, Portugal

2013 - 2014	Professor Auxiliar (Docente Universitário)	Universidade de Lisboa Faculdade de Medicina, Portugal

Outros

	Categoria Profissional Instituição de acolhimento	Empregador
2016 - Atual	Director of the Clinical Research Center	Hospital de Santa Maria, Portugal

2013 - Atual	Coordinator of the Oncology Committee	Hospital de Santa Maria, Portugal

2009 - Atual	Chief of Oncology Division	Hospital de Santa Maria, Portugal

2005 - Atual	Director of the Oncology Department	Hospital de Santa Maria, Portugal

1993 - 1998	Assistant Physician in oncology	Hospital de Santa Maria, Portugal
	Hospital de Santa Maria, Portugal
1990 - 1993	Fellowship in Medical Oncology	Hospital de Santa Maria, Portugal
	Instituto Português de Oncologia de Lisboa Francisco Gentil EPE, Portugal
1992 - 1992	Visiting fellow	Penn State, Estados Unidos
	Penn State Health Milton S Hershey Medical Center Department of Medicine, Estados Unidos
1988 - 1990	Residency and Fellowship in Internal Medicine	Hospital de Santa Maria, Portugal
	Hospital de Santa Maria, Portugal

Projetos

Bolsa

	Designação	Financiadores
2018 - 2021	Inervação patológica em metástases ósseas: OSTEOCLASTOS, o que estão a fazer? PTDC/MED-PAT/30158/2017 Investigador	Fundação para a Ciência e a Tecnologia
2016 - 2019	PERSEIDS - Personalizing cancer therapy through integrated modeling and decision PTDC/EMS-SIS/0642/2014 Investigador	Fundação para a Ciência e a Tecnologia
2016 - 2018	ReTuBi: Towards outstanding research and training in tumour 692322 Investigador	European Commission
2016 - 2017	The prognostic role of RANK SNP rs34945627 in breast cancer patients FPJ001034 Investigador	Fundo iMM-Laço
2015 - 2016	IMM Bridge Grant 2015 FPJ000880 Investigador responsável	Fundação para a Ciência e a Tecnologia
2014 - 2016	Involvement of PLCY1 in the resistance Mechanism to Anti-EGFR Therapy in Metastatic Colorectal Cancer FPJ000858 Investigador	Liga Portuguesa Contra o Cancro
2014 - 2016	Mechanisms of invasion and progression of cancer in bone: Molecular profiling of matrix and adhesion-related molecules in metastatic disease FPJ000858 Investigador	Liga Portuguesa Contra o Cancro
2013 - 2015	Metal-based Multimodal Probes for Breast Cancer Imaging Targeting Y1-NPY Receptors: Synthesis, Characterization and Pre-clinical Evaluation FCT-ANR/QEQ-MED/0117/2012	Fundação para a Ciência e a Tecnologia
2011 - 2015	Molecular markers in multiple myeloma FPJ000546 Investigador
2011 - 2014	Mechanisms of invasion and progression in metastatic bone disease and outcomes in HER2 positive metastatic breast cancer HMSP-ICS/0004/2011	Fundação para a Ciência e a Tecnologia
2011 - 2014	Multi-Functional Bone Seeking Agents for the Treatment of Skeletal Metastatic Disease PTDC/SAU-OBD/108608/2008 PTDC/QUI-QUI/115712/2009 Investigador	Fundação para a Ciência e a Tecnologia Concluído
2012 - 2013	Long Term Bisphosphonates FPJ000575 Investigador responsável

Projeto

	Designação	Financiadores
2022/01/17 - 2025/01/16	Multifunctional nano-immunotherapy for melanoma brain metastases treatment PTDC/BTM-SAL/4350/2021 Universidade de Lisboa Instituto de Investigação do Medicamento, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Em curso
2018/09/01 - 2021/08/31	Physiopathology and clinical implications of the RANK c.1386C>T R450W mutation in breast cancer patients PTDC/MED-ONC/28636/2017 Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal Fundação Calouste Gulbenkian, Portugal Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído
2016/12/01 - 2020/11/30	Promoção do avanço significativo do conhecimento na área de medicina de precisão e sua translação para benefício da sociedade SAICTPAC/0021/2015 Instituto de Medicina Molecular João Lobo Antunes, Portugal Instituto de Engenharia de Sistemas e Computadores Investigação e Desenvolvimento em Lisboa, Portugal Associação do Instituto Superior Técnico para a Investigação e Desenvolvimento, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Em curso
2014/07/01 - 2016/12/30	Relative effectivity of aromatase inhibitors versus tamoxifen in patients with early breast cancer HMSP-ICJ/0007/2013 Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal Dana-Farber Cancer Institute, Estados Unidos Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído
2013/06/01 - 2016/11/30	Sistemas Moleculares e Nano para Teranóstica de Cancro EXCL/QEQ-MED/0233/2012 Associação do Instituto Superior Técnico para a Investigação e Desenvolvimento, Portugal Universidade de Lisboa Instituto Superior Tecnico Campus Tecnológico e Nuclear, Portugal Universidade Nova de Lisboa Instituto de Tecnologia Química e Biológica, Portugal Universidade de Aveiro, Portugal Universidade de Coimbra, Portugal Instituto de Medicina Molecular João Lobo Antunes, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído
2014/04/01 - 2015/09/30	CancerSys - Modelação multiscala para a terapia personalizada de metástases ósseas EXPL/EMS-SIS/1954/2013 Instituto de Engenharia Mecânica, Portugal Instituto de Engenharia Mecânica, Portugal Instituto de Telecomunicações, Portugal Instituto de Engenharia de Sistemas e Computadores Investigação e Desenvolvimento em Lisboa, Portugal Centro Hospitalar Universitário Lisboa Norte EPE, Portugal Instituto de Medicina Molecular João Lobo Antunes, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído
2014/04/01 - 2015/03/31	Mechanisms and relevance of Phospholipase C epsilon downregulation in cancer EXPL/BIM-ONC/1048/2013 Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído
2011/11/01 - 2014/04/30	Oncobiologia: novas ferramentas educativas para as futuras gerações de investigadores clínicos HMSP-PCM/0007/2010 Instituto de Medicina Molecular João Lobo Antunes, Portugal Centro Hospitalar Universitário Lisboa Norte EPE, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído
2011/03/01 - 2014/02/28	Synthesis, Characterization and Biological Assessment of Multi-Functional Bone-Seeking Agents PTDC/QUI-QUI/115712/2009 Universidade de Lisboa Instituto Superior Técnico, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído
2009/01/01 - 2012/09/29	Assinaturas Moleculares de Prognóstico em Cancro Colorectal (AMPCC) PIC/IC/82821/2007 Instituto de Medicina Molecular João Lobo Antunes, Portugal Centro Hospitalar Universitário Lisboa Norte EPE, Portugal Universidade de Lisboa Instituto de Medicina Molecular João Lobo Antunes, Portugal	Fundação para a Ciência e a Tecnologia Concluído

Outro

	Designação	Financiadores
2017 - Atual	Oncodynamics FPJ000900 Investigador responsável
2013 - Atual	Global Cancer Genomic Consortium FPJ000703 Investigador responsável	AstraZeneca Produtos Farmacêuticos Lda
2013 - Atual	GCGC Meeting FPJ000753 Investigador responsável	Fundação para a Ciência e a Tecnologia
2015 - 2018	Analysis of RANK protein expression in Cohort 2 using immunohistochemistry (IHC) in 70 matched primary breast cancer tumors and distant metastasis FPJ000168 Investigador responsável	Amgen Inc
2008 - 2018	Oncology Series FPJ000269 Investigador responsável	Pfizer Portugal
2016 - 2017	Molecular Markers of Bone Metastases FPJ000129 Investigador responsável
2016 - 2016	CORBIE - Characterizing the biological role of clinically relevant collagen type I fragments in metastatic breast cancer FPJ001010 Investigador responsável
2015 - 2016	Luminal-type breast cancer: prognostic value of RANK-positive lymphatic nodes FPJ000288 Investigador	AstraZeneca Produtos Farmacêuticos Lda
2013 - 2016	Molecular Characterization of Breast Cancers FPJ000757 Investigador responsável	Novartis Farmaceutica
2013 - 2016	Collagen in Breast cancer FPJ000755 Investigador responsável
2013 - 2014	c-Met, p-c-Met, and HGF IHC in Bone Metastases FPJ000777 Investigador	Merck SA
2012 - 2013	Cachexia in pancreatic cancer FPJ000641 Investigador responsável	Pfizer Portugal

Produções

Publicações

Artigo em revista

Tito Palmela Leitão; Miguel Miranda; Tiago Oliveira; Pedro Oliveira; Inês Pereira Pereira; José Palma dos Reis; Isabel Fernandes; et al. "Laparoscopic Vena Cava Thrombectomy and Radical Nephrectomy in a Malignant Pheochromocytoma Case". Acta Urológica Portuguesa (2022): https://doi.org/10.24915/aup.37.1-2.162.
10.24915/aup.37.1-2.162
Gisela Gordino; Sara Costa-Pereira; Patrícia Corredeira; Patrícia Alves; Luís Costa; Anita Q Gomes; Bruno Silva-Santos; Julie C Ribot. "MicroRNA-181a restricts human ¿d T cell differentiation by targeting Map3k2 and Notch2". EMBO reports (2022): https://doi.org/10.15252/embr.202052234.
10.15252/embr.202052234
Cruz-Duarte, Raquel; Rebelo de Almeida, Cátia; Negrão, Magda; Fernandes, Afonso; Borralho, Paula; Sobral, Daniel; Gallego-Paez, Lina M.; et al. "Predictive and Therapeutic Implications of a Novel PLC¿1/SHP2-Driven Mechanism of Cetuximab Resistance in Metastatic Colorectal Cancer". Clinical Cancer Research (2022): http://dx.doi.org/10.1158/1078-0432.ccr-21-1992.
10.1158/1078-0432.ccr-21-1992
Cláudia Lopes; Paulina Piairo; Alexandre Chícharo; Sara Abalde-Cela; Liliana R. Pires; Patrícia Corredeira; Patrícia Alves; et al. "HER2 Expression in Circulating Tumour Cells Isolated from Metastatic Breast Cancer Patients Using a Size-Based Microfluidic Device". Cancers (2021): https://doi.org/10.3390/cancers13174446.
10.3390/cancers13174446
Alpuim Costa, Diogo; Nobre, José Guilherme; Batista, Marta Vaz; Ribeiro, Catarina; Calle, Catarina; Cortes, Alfonso; Marhold, Maximilian; et al. "Human Microbiota and Breast Cancer—Is There Any Relevant Link?—A Literature Review and New Horizons Toward Personalised Medicine". Frontiers in Microbiology 12 (2021): http://dx.doi.org/10.3389/fmicb.2021.584332.
10.3389/fmicb.2021.584332
Golkaram, Mahdi; Salmans, Michael L.; Kaplan, Shannon; Vijayaraghavan, Raakhee; Martins, Marta; Khan, Nafeesa; Garbutt, Cassandra; et al. "HERVs establish a distinct molecular subtype in stage II/III colorectal cancer with poor outcome". npj Genomic Medicine 6 1 (2021): http://dx.doi.org/10.1038/s41525-021-00177-w.
10.1038/s41525-021-00177-w
R. Ferreira, Arlindo; Ferreira, Sofia; Lambertini, Matteo; Maurer, Christian; Martel, Samuel; Costa, Luis; Ponde, Noam; de Azambuja, Evandro. "Association between pertuzumab-associated diarrhoea and rash and survival outcomes in patients with HER2-positive metastatic breast cancer: Exploratory analysis from the CLEOPATRA trial". European Journal of Cancer 144 (2021): 351-359. http://dx.doi.org/10.1016/j.ejca.2020.11.023.
10.1016/j.ejca.2020.11.023
Fernandes, Isabel; Melo-Alvim, Cecília; Lopes-Brás, Raquel; Esperança-Martins, Miguel; Costa, Luís. "Osteosarcoma Pathogenesis Leads the Way to New Target Treatments". International Journal of Molecular Sciences 22 2 (2021): 813. http://dx.doi.org/10.3390/ijms22020813.
10.3390/ijms22020813
Silva Paiva, Rita; Gomes, Inês; Casimiro, Sandra; Fernandes, Isabel; Costa, Luís. "c-Met expression in renal cell carcinoma with bone metastases". Journal of Bone Oncology 25 (2020): 100315. http://dx.doi.org/10.1016/j.jbo.2020.100315.
10.1016/j.jbo.2020.100315
Peixoto, Carolina; Lopes, Marta B.; Martins, Marta; Costa, Luís; Vinga, Susana. "TCox: Correlation-Based Regularization Applied to Colorectal Cancer Survival Data". Biomedicines 8 11 (2020): 488. http://dx.doi.org/10.3390/biomedicines8110488.
10.3390/biomedicines8110488
Coleman, Robert E.; Croucher, Peter I.; Padhani, Anwar R.; Clézardin, Philippe; Chow, Edward; Fallon, Marie; Guise, Theresa; et al. "Bone metastases". Nature Reviews Disease Primers 6 1 (2020): http://dx.doi.org/10.1038/s41572-020-00216-3.
10.1038/s41572-020-00216-3
Melo-Alvim, Cecília; Miguel-Semedo, Patrícia; Paiva, Rita Silva; Lobo-Martins, Soraia; Luna-Pais, Helena; Costa, Ana Lúcia; Santos, Ana Rita; et al. "Pretreatment hemoglobin level as a prognostic factor in patients with locally advanced head and neck squamous cell carcinoma". Reports of Practical Oncology & Radiotherapy 25 5 (2020): 768-774. http://dx.doi.org/10.1016/j.rpor.2020.07.002.
10.1016/j.rpor.2020.07.002
Caiado, Joana; Brás, Rita; Paulino, Marisa; Costa, Luis; Castells, Mariana. "Rapid desensitization to antineoplastic drugs in an outpatient immunoallergology clinic". Annals of Allergy, Asthma & Immunology 125 3 (2020): 325-333.e1. http://dx.doi.org/10.1016/j.anai.2020.04.017.
10.1016/j.anai.2020.04.017
Lobo-Martins, Soraia; Ferreira, Arlindo R.; Mansinho, André; Casimiro, Sandra; Leitzel, Kim; Ali, Suhail; Lipton, Allan; Costa, Luís. "Impact of Extraskeletal Metastases on Skeletal-Related Events in Metastatic Castration-Resistant Prostate Cancer with Bone Metastases". Cancers 12 8 (2020): 2034. http://dx.doi.org/10.3390/cancers12082034.
10.3390/cancers12082034
Kakoo Brioso, Estela; Ferreira Cristina, Sérgio; Costa, Luis; Ouakinin, Silvia. "Correlation between emotional regulation and peripheral lymphocyte counts in colorectal cancer patients". PeerJ 8 (2020): e9475. http://dx.doi.org/10.7717/peerj.9475.
10.7717/peerj.9475
Chowdhury, Simon; Bjartell, Anders; Lumen, Nicolaas; Maroto, Pablo; Paiss, Thomas; Gomez-Veiga, Francisco; Birtle, Alison; et al. "Real-World Outcomes in First-Line Treatment of Metastatic Castration-Resistant Prostate Cancer: The Prostate Cancer Registry". Targeted Oncology 15 3 (2020): 301-315. http://dx.doi.org/10.1007/s11523-020-00720-2.
10.1007/s11523-020-00720-2
Martins Cavaco, Ana C.; Dâmaso, Sara; Casimiro, Sandra; Costa, Luís. "Collagen biology making inroads into prognosis and treatment of cancer progression and metastasis". Cancer and Metastasis Reviews 39 3 (2020): 603-623. http://dx.doi.org/10.1007/s10555-020-09888-5.
10.1007/s10555-020-09888-5
Gomes, Inês; de Almeida, Bernardo P.; Dâmaso, Sara; Mansinho, André; Correia, Inês; Henriques, Sara; Cruz-Duarte, Raquel; et al. "Expression of receptor activator of NFkB (RANK) drives stemness and resistance to therapy in ER+HER2- breast cancer". Oncotarget 11 19 (2020): 1714-1728. http://dx.doi.org/10.18632/oncotarget.27576.
10.18632/oncotarget.27576
Coelho, Sara; Rego, Inês Brandão; Dionísio, Maria Rita; Cavaco-Silva, Joana; Semedo, Patrícia Miguel; Pavão, Francisco; Leite, Ricardo Baptista; Costa, Luís. "360 Health Analysis (H360) – A Proposal for an Integrated Vision of Breast Cancer in Portugal". European Journal of Breast Health 16 2 (2020): 91-98. http://dx.doi.org/10.5152/ejbh.2020.5144.
Publicado • 10.5152/ejbh.2020.5144
Alvim, Cecília M; Mansinho, André; Paiva, Rita S; Brás, Raquel; Semedo, Patrícia M; Lobo-Martins, Soraia; da Ponte, Carolina B; et al. "Prognostic factors for patients treated with abiraterone". Future Science OA 6 2 (2020): FSO436. http://dx.doi.org/10.2144/fsoa-2019-0079.
Publicado • 10.2144/fsoa-2019-0079
Marques da Costa, Pedro; Tato Marinho, Rui; Cortez-Pinto, Helena; Costa, Luís; Velosa, José. "Twenty-Five Years of Increasing Mortality From Pancreatic Cancer in Portugal". Pancreas 49 1 (2020): e2-e3. http://dx.doi.org/10.1097/mpa.0000000000001446.
10.1097/mpa.0000000000001446
Gil Marques, Filipa; Poli, Esmeralda; Malaquias, João; Carvalho, Tânia; Portêlo, Ana; Ramires, Afonso; Aldeia, Fernando; et al. "Low doses of ionizing radiation activate endothelial cells and induce angiogenesis in peritumoral tissues". Radiotherapy and Oncology 141 (2019): 256-261. http://dx.doi.org/10.1016/j.radonc.2019.06.035.
Publicado • 10.1016/j.radonc.2019.06.035
Willumsen, Nicholas; Ali, Suhail M.; Leitzel, Kim; Drabick, Joseph J.; Yee, Nelson; Polimera, Hyma V.; Nagabhairu, Vinod; et al. "Collagen fragments quantified in serum as measures of desmoplasia associate with survival outcome in patients with advanced pancreatic cancer". Scientific Reports 9 1 (2019): http://dx.doi.org/10.1038/s41598-019-56268-3.
Publicado • 10.1038/s41598-019-56268-3
Ferreira, Arlindo R.; Ribeiro, Joana; Miranda, Ana; Mayer, Alexandra; Passos-Coelho, José Luís; Brito, Margarida; Fernandes, João; et al. "Effectiveness of Adjuvant Ovarian Function Suppression in Premenopausal Women With Early Breast Cancer: A Multicenter Cohort Study". Clinical Breast Cancer 19 5 (2019): e654-e667. http://dx.doi.org/10.1016/j.clbc.2019.06.003.
Publicado • 10.1016/j.clbc.2019.06.003
Maria Rita Dionísio; André Mansinho; Catarina Abreu; Joana Cavaco-Silva; Sandra Casimiro; Luís Costa. "Clinical and translational pharmacology of drugs for the prevention and treatment of bone metastases and cancer-induced bone loss". British Journal of Clinical Pharmacology 85 6 (2019): 1114-1124. https://doi.org/10.1111/bcp.13852.
10.1111/bcp.13852
von Moos, Roger; Costa, Luis; Gonzalez-Suarez, Eva; Terpos, Evangelos; Niepel, Daniela; Body, Jean–Jacques. "Management of bone health in solid tumours: From bisphosphonates to a monoclonal antibody". Cancer Treatment Reviews 76 (2019): 57-67. http://dx.doi.org/10.1016/j.ctrv.2019.05.003.
Publicado • 10.1016/j.ctrv.2019.05.003
André Mansinho; Arlindo R. Ferreira; Sandra Casimiro; Irina Alho; Inês Vendrell; Ana Lúcia Costa; Rita Sousa; et al. "Levels of Circulating Fibroblast Growth Factor 23 (FGF23) and Prognosis in Cancer Patients with Bone Metastases". International Journal of Molecular Sciences (2019): http://www.mdpi.com/1422-0067/20/3/695.
10.3390/ijms20030695
Loureiro, Hugo; Carrasquinha, Eunice; Alho, Irina; Ferreira, Arlindo R.; Costa, Luís; Carvalho, Alexandra M.; Vinga, Susana. "Modelling cancer outcomes of bone metastatic patients: combining survival data with N-Telopeptide of type I collagen (NTX) dynamics through joint models". BMC Medical Informatics and Decision Making 19 1 (2019): http://dx.doi.org/10.1186/s12911-018-0728-1.
Publicado • 10.1186/s12911-018-0728-1
Vendrell, Ines; Ferreira, Arlindo R.; Abrunhosa-Branquinho, André N.; Semedo, Patrícia Miguel; Pulido, Catarina F.; Jorge, Marília; Pina, Maria Filomena de; Pinto, Conceição; Costa, Luís. "Chemoradiotherapy completion and neutropenia risk in HIV patients with cervical cancer". Medicine 97 30 (2018): e11592. http://dx.doi.org/10.1097/md.0000000000011592.
Publicado • 10.1097/md.0000000000011592
Kakoo-Brioso, Estela; Costa, Luís; Ouakinin, Sílvia. "Association of Anger Expression-Out with NK Cell Counts in Colorectal Cancer Patients". Acta Médica Portuguesa 31 3 (2018): 152. http://dx.doi.org/10.20344/amp.9573.
Publicado • 10.20344/amp.9573
Ferreira, Arlindo R.; Palha, Ana; Correia, Lurdes; Filipe, Pedro; Rodrigues, Vasco; Miranda, Ana; André, Rosário; et al. "Treatment adoption and relative effectiveness of aromatase inhibitors compared to tamoxifen in early breast cancer: A multi-institutional observational study". The Breast 37 (2018): 107-113. http://dx.doi.org/10.1016/j.breast.2017.11.003.
Publicado • 10.1016/j.breast.2017.11.003
Costa, Luís; Ferreira, Arlindo R. "Adjuvant zoledronic acid to treat breast cancer: not for all". The Lancet Oncology 18 11 (2017): 1437-1439. http://dx.doi.org/10.1016/s1470-2045(17)30695-2.
Publicado • 10.1016/s1470-2045(17)30695-2
Ferreira, A.R.; Bettencourt, M.; Alho, I.; Costa, A.L.; Sousa, A.R.; Mansinho, A.; Abreu, C.; et al. "Serum YB-1 (Y-box binding protein 1) as a biomarker of bone disease progression in patients with breast cancer and bone metastases". Journal of Bone Oncology 6 (2017): 16-21. http://dx.doi.org/10.1016/j.jbo.2017.01.002.
Publicado • 10.1016/j.jbo.2017.01.002
Pulido, Catarina; Vendrell, Inês; Ferreira, Arlindo R; Casimiro, Sandra; Mansinho, André; Alho, Irina; Costa, Luís. "Bone metastasis risk factors in breast cancer". ecancermedicalscience 11 (2017): http://dx.doi.org/10.3332/ecancer.2017.715.
Publicado • 10.3332/ecancer.2017.715
von Moos, Roger; Costa, Luis; Ripamonti, Carla Ida; Niepel, Daniela; Santini, Daniele. "Improving quality of life in patients with advanced cancer: Targeting metastatic bone pain". European Journal of Cancer 71 (2017): 80-94. http://dx.doi.org/10.1016/j.ejca.2016.10.021.
Publicado • 10.1016/j.ejca.2016.10.021
Helena Luna Pais; Irina Alho; Inês Vendrell; André Mansinho; Luís Costa. "Radionuclides in oncology clinical practice – review of the literature". Dalton Transactions 46 42 (2017): 14475-14487. https://doi.org/10.1039/C7DT01929G.
10.1039/C7DT01929G
Ribeiro, Elisabete; Alho, Irina; Marques, Fernanda; Gano, Lurdes; Correia, Isabel; Correia, João D.G.; Casimiro, Sandra; et al. "Radiolabeled block copolymer micelles for image-guided drug delivery". International Journal of Pharmaceutics 515 1-2 (2016): 692-701. http://dx.doi.org/10.1016/j.ijpharm.2016.11.004.
Publicado • 10.1016/j.ijpharm.2016.11.004
R. Ferreira, Arlindo; Palha, Ana; Correia, Lurdes; Filipe, Pedro; Rodrigues, Vasco; Costa, Luís; Miranda, Ana; et al. "Variation in type of adjuvant chemotherapy received among patients with stage I breast cancer: A multi-institutional Portuguese cohort study". The Breast 29 (2016): 68-73. http://dx.doi.org/10.1016/j.breast.2016.07.004.
Publicado • 10.1016/j.breast.2016.07.004
Fiuza, Manuela; Ribeiro, Leonor; Magalhães, Andreia; Sousa, Ana Rita; Nobre Menezes, Miguel; Jorge, Marília; Costa, Luís; Pinto, Fausto José. "Organização e implementação de uma consulta de cardio-oncologia". Revista Portuguesa de Cardiologia 35 9 (2016): 485-494. http://dx.doi.org/10.1016/j.repc.2016.04.006.
Publicado • 10.1016/j.repc.2016.04.006
Casimiro, Sandra; Ferreira, Arlindo; Mansinho, André; Alho, Irina; Costa, Luis. "Molecular Mechanisms of Bone Metastasis: Which Targets Came from the Bench to the Bedside?". International Journal of Molecular Sciences 17 9 (2016): 1415. http://dx.doi.org/10.3390/ijms17091415.
Publicado • 10.3390/ijms17091415
Ferreira, Arlindo R.; Alho, Irina; Shan, Ning; Matias, Margarida; Faria, Mariana; Casimiro, Sandra; Leitzel, Kim; et al. "N-Telopeptide of Type I Collagen Long-Term Dynamics in Breast Cancer Patients With Bone Metastases: Clinical Outcomes and Influence of Extraskeletal Metastases". The Oncologist 21 12 (2016): 1418-1426. http://dx.doi.org/10.1634/theoncologist.2015-0527.
Publicado • 10.1634/theoncologist.2015-0527
Tato-Costa, Joana; Casimiro, Sandra; Pacheco, Teresa; Pires, Ricardo; Fernandes, Afonso; Alho, Irina; Pereira, Pedro; et al. "Therapy-Induced Cellular Senescence Induces Epithelial-to-Mesenchymal Transition and Increases Invasiveness in Rectal Cancer". Clinical Colorectal Cancer 15 2 (2016): 170-178.e3. http://dx.doi.org/10.1016/j.clcc.2015.09.003.
Publicado • 10.1016/j.clcc.2015.09.003
Ferreira, Arlindo; Alho, Irina; Vendrell, Inês; Melo, Marta; Brás, Raquel; Costa, Ana Lúcia; Sousa, Ana Rita; et al. "The prognostic role of RANK SNP rs34945627 in breast cancer patients with bone metastases". Oncotarget 7 27 (2016): http://dx.doi.org/10.18632/oncotarget.9356.
Publicado • 10.18632/oncotarget.9356
Hadji, P.; Coleman, R.E.; Wilson, C.; Powles, T.J.; Clézardin, P.; Aapro, M.; Costa, L.; et al. "Adjuvant bisphosphonates in early breast cancer: consensus guidance for clinical practice from a European Panel". Annals of Oncology 27 3 (2016): 379-390. http://dx.doi.org/10.1093/annonc/mdv617.
Publicado • 10.1093/annonc/mdv617
Coelho, Rui Moura; Lemos, João Miranda; Alho, Irina; Valério, Duarte; Ferreira, Arlindo R; Costa, Luís; Vinga, Susana. "Dynamic modeling of bone metastasis, microenvironment and therapy". Journal of Theoretical Biology 391 (2016): 1-12. http://dx.doi.org/10.1016/j.jtbi.2015.11.024.
Publicado • 10.1016/j.jtbi.2015.11.024
Mendes, Diogo; Alves, Carlos; Afonso, Noémia; Cardoso, Fátima; Passos-Coelho, José Luís; Costa, Luís; Andrade, Sofia; Batel-Marques, Francisco. "The benefit of HER2-targeted therapies on overall survival of patients with metastatic HER2-positive breast cancer – a systematic review". Breast Cancer Research 17 1 (2015): http://dx.doi.org/10.1186/s13058-015-0648-2.
Publicado • 10.1186/s13058-015-0648-2
Body, Jean-Jacques; Bone, Henry G.; de Boer, Richard H.; Stopeck, Alison; Van Poznak, Catherine; Damião, Ronaldo; Fizazi, Karim; et al. "Hypocalcaemia in patients with metastatic bone disease treated with denosumab". European Journal of Cancer 51 13 (2015): 1812-1821. http://dx.doi.org/10.1016/j.ejca.2015.05.016.
Publicado • 10.1016/j.ejca.2015.05.016
Body, Jean-Jacques; Pereira, João; Sleeboom, Harm; Maniadakis, Nikos; Terpos, Evangelos; Acklin, Yves Pascal; Finek, Jindrich; et al. "Health resource utilization associated with skeletal-related events: results from a retrospective European study". The European Journal of Health Economics 17 6 (2015): 711-721. http://dx.doi.org/10.1007/s10198-015-0716-7.
Publicado • 10.1007/s10198-015-0716-7
Body, Jean-Jacques; Casimiro, Sandra; Costa, Luís. "Targeting bone metastases in prostate cancer: improving clinical outcome". Nature Reviews Urology 12 6 (2015): 340-356. http://dx.doi.org/10.1038/nrurol.2015.90.
Publicado • 10.1038/nrurol.2015.90
Ferreira, Arlindo; Alho, Irina; Casimiro, Sandra; Costa, Luís. "Bone remodeling markers and bone metastases: From cancer research to clinical implications". BoneKEy Reports 4 (2015): http://dx.doi.org/10.1038/bonekey.2015.35.
Publicado • 10.1038/bonekey.2015.35
Matias, Margarida; Casa-Nova, Mafalda; Faria, Mariana; Pires, Ricardo; Tato-Costa, Joana; Ribeiro, Leonor; Costa, Luis. "Prognostic Factors after Liver Resection for Colorectal Liver Metastasis". Acta Médica Portuguesa 28 3 (2015): 357. http://dx.doi.org/10.20344/amp.4816.
Publicado • 10.20344/amp.4816
Vendrell, I.; Macedo, D.; Alho, I.; Dionísio, M. R.; Costa, L.. "Treatment of Cancer Pain by Targeting Cytokines". Mediators of Inflammation 2015 (2015): 1-11. http://dx.doi.org/10.1155/2015/984570.
Publicado • 10.1155/2015/984570
Costa, Ana Lúcia; Abreu, Catarina; Pacheco, Teresa Raquel; Macedo, Daniela; Sousa, Ana Rita; Pulido, Catarina; Quintela, António; Costa, Luís. "Prevention of Nausea and Vomiting in Patients Undergoing Oral Anticancer Therapies for Solid Tumors". BioMed Research International 2015 (2015): 1-7. http://dx.doi.org/10.1155/2015/309601.
Publicado • 10.1155/2015/309601
Costa, Luis. "Bisphosphonates in adjuvant setting for breast cancer". Current Opinion in Supportive and Palliative Care 8 4 (2014): 414-419. http://dx.doi.org/10.1097/spc.0000000000000101.
Publicado • 10.1097/spc.0000000000000101
Casimiro, Sandra; Fernandes, Afonso; Oliveira, António Gouveia; Franco, Marco; Pires, Ricardo; Peres, Mafalda; Matias, Margarida; et al. "Metadherin expression and lung relapse in patients with colorectal carcinoma". Clinical & Experimental Metastasis 31 6 (2014): 689-696. http://dx.doi.org/10.1007/s10585-014-9659-0.
Publicado • 10.1007/s10585-014-9659-0
Costa, Luis. "Which bisphosphonate to treat bone metastases?". The Lancet Oncology 15 1 (2014): 15-16. http://dx.doi.org/10.1016/s1470-2045(13)70583-7.
Publicado • 10.1016/s1470-2045(13)70583-7
Henry D; Vadhan-Raj S; Hirsh V; von Moos R; Hungria V; Costa L; Woll PJ; et al. "Delaying skeletal-related events in a randomized phase 3 study of denosumab versus zoledronic acid in patients with advanced cancer: an analysis of data from patients with solid tumors.". Supportive Care in Cancer 22 3 (2013): 679-687. http://europepmc.org/abstract/med/24162260.
Publicado • 10.1007/s00520-013-2022-1
Caiado, Joana; Venemalm, Lennart; Pereira-Santos, Maria Conceição; Costa, Luis; Barbosa, Manuel Pereira; Castells, Mariana. "Carboplatin-, Oxaliplatin-, and Cisplatin–specific IgE: Cross-reactivity and Value in the Diagnosis of Carboplatin and Oxaliplatin Allergy". The Journal of Allergy and Clinical Immunology: In Practice 1 5 (2013): 494-500. http://dx.doi.org/10.1016/j.jaip.2013.06.002.
Publicado • 10.1016/j.jaip.2013.06.002
Coleman, Robert E.; Lipton, Allan; Costa, Luis; Cook, Richard J.; Lee, Ker-Ai; Saad, Fred; Brown, Janet E.; et al. "Possible survival benefits from zoledronic acid treatment in patients with bone metastases from solid tumours and poor prognostic features—An exploratory analysis of placebo-controlled trials". Journal of Bone Oncology 2 2 (2013): 70-76. http://dx.doi.org/10.1016/j.jbo.2013.01.002.
Publicado • 10.1016/j.jbo.2013.01.002
Costa, Luis; Fizazi, Karim; Saad, Fred; Brown, Janet Elizabeth; Von Moos, Roger; Oudard, Stephane; Sternberg, Cora N.; et al. "Denosumab and zoledronic acid treatment in patients with genitourinary cancers and bone metastases.". Journal of Clinical Oncology 31 15_suppl (2013): 5079-5079. http://dx.doi.org/10.1200/jco.2013.31.15_suppl.5079.
Publicado • 10.1200/jco.2013.31.15_suppl.5079
Casimiro, Sandra; Mohammad, Khalid S.; Pires, Ricardo; Tato-Costa, Joana; Alho, Irina; Teixeira, Rui; Carvalho, António; et al. "RANKL/RANK/MMP-1 Molecular Triad Contributes to the Metastatic Phenotype of Breast and Prostate Cancer Cells In Vitro". PLoS ONE 8 5 (2013): e63153. http://dx.doi.org/10.1371/journal.pone.0063153.
Publicado • 10.1371/journal.pone.0063153
Alho I; Costa L; Bicho M; Coelho C. "Characterization of low molecular weight protein tyrosine phosphatase isoforms in human breast cancer epithelial cell lines.". (2013): http://europepmc.org/abstract/med/23645747.
Alho, Irina; Costa, Luís; Bicho, Manuel; Coelho, Constança; Alho I; Costa L; Bicho M; Coelho C. "The role of low-molecular-weight protein tyrosine phosphatase (LMW-PTP ACP1) in oncogenesis". Tumor Biology 34 4 (2013): 1979-1989. http://dx.doi.org/10.1007/s13277-013-0784-1.
Publicado • 10.1007/s13277-013-0784-1
Horvath A; Pakala SB; Mudvari P; Reddy SD; Ohshiro K; Casimiro S; Pires R; et al. "Novel insights into breast cancer genetic variance through RNA sequencing.". (2013): http://europepmc.org/abstract/med/23884293.
10.1038/srep02256
Alho I; Costa L; Bicho M; Coelho C. "Low Molecular Weight Protein Tyrosine Phosphatase Isoforms Regulate Breast Cancer Cells Migration through a RhoA Dependent Mechanism.". (2013): http://europepmc.org/abstract/med/24086724.
10.1371/journal.pone.0076307
Casimiro, S.; Alho, I.; Bettencourt, M.; Pires, R.; Lipton, A.; Costa, L.. "RANKL enhances the effect of an antagonist of inhibitor of apoptosis proteins (cIAPs) in RANK-positive breast cancer cells". Journal of Bone Oncology 2 3 (2013): 116-122. http://www.scopus.com/inward/record.url?eid=2-s2.0-84880799147&partnerID=MN8TOARS.
Publicado • 10.1016/j.jbo.2013.07.001
Pakala, S.B.; Rayala, S.K.; Wang, R.-A.; Ohshiro, K.; Mudvari, P.; Reddy, S.D.N.; Zheng, Y.; et al. "MTA1 promotes STAT3 transcription and pulmonary metastasis in breast cancer". Cancer Research 73 12 (2013): 3761-3770. http://www.scopus.com/inward/record.url?eid=2-s2.0-84879076893&partnerID=MN8TOARS.
10.1158/0008-5472.CAN-12-3998
Fernandes, C.; Monteiro, S.; Mendes, P.; Gano, L.; Marques, F.; Casimiro, S.; Costa, L.; et al. "Biological assessment of novel bisphosphonate-containing 99mTc/Re-organometallic complexes". Journal of Organometallic Chemistry 760 (2013): 197-204. http://www.scopus.com/inward/record.url?eid=2-s2.0-84886959842&partnerID=MN8TOARS.
Publicado • 10.1016/j.jorganchem.2013.10.038
Macedo, Daniela; Amaral, Teresa; Fernandes, Isabel; Sousa, Ana Rita; Costa, Ana Lúcia; Távora, Isabel; Quintela, António; Cortes, Paulo; Costa, Luís. "The Treatment of Liver Metastases in Patients with Neuroendocrine Tumors in 2012". ISRN Hepatology 2013 (2013): 1-9. http://dx.doi.org/10.1155/2013/702167.
Publicado • 10.1155/2013/702167
Hadji P; Aapro M; Costa L; Gnant M. "Antiresorptive treatment options and bone health in cancer patients-safety profiles and clinical considerations.". (2012): http://europepmc.org/abstract/med/22482938.
10.1016/j.ctrv.2012.03.002
Global Cancer Genomics Consortium. "The Global Cancer Genomics Consortium: interfacing genomics and cancer medicine.". (2012): http://europepmc.org/abstract/med/22628426.
10.1158/0008-5472.CAN-12-1054
Clemons M; Russell K; Costa L; Addison CL. "Adjuvant bisphosphonate treatment for breast cancer: why did something so elegant become so complicated?". (2012): http://europepmc.org/abstract/med/22562125.
10.1007/s10549-012-2077-6
Costa, Luis; Lipton, Allan; Hadji, Peyman; Chen, Yin-Miao; Kosmidis, Paris; Costa L; Lipton A; et al. "Treatment of bone metastases before the onset of pain". International Journal of Clinical Oncology 18 3 (2012): 531-538. http://dx.doi.org/10.1007/s10147-012-0414-8.
Publicado • 10.1007/s10147-012-0414-8
Amaral TM; Macedo D; Fernandes I; Costa L. "Castration-resistant prostate cancer: mechanisms, targets, and treatment.". (2012): http://europepmc.org/abstract/med/22530130.
10.1155/2012/327253
Fernandes, I.; Pacheco, T.R.; Costa, A.; Santos, A.C.; Fernandes, A.R.; Santos, M.; Oliveira, A.G.; et al. "Prognostic significance of AKT/mTOR signaling in advanced neuroendocrine tumors treated with somatostatin analogs". OncoTargets and Therapy 5 (2012): 409-416. http://www.scopus.com/inward/record.url?eid=2-s2.0-84873906537&partnerID=MN8TOARS.
10.2147/OTT.S36330
Casimiro, S.; Luis, I.; Fernandes, A.; Pires, R.; Pinto, A.; Gouveia, A.G.; Francisco, A.F.; et al. "Analysis of a bone metastasis gene expression signature in patients with bone metastasis from solid tumors". Clinical and Experimental Metastasis 29 2 (2012): 155-164. http://www.scopus.com/inward/record.url?eid=2-s2.0-84857167793&partnerID=MN8TOARS.
10.1007/s10585-011-9438-0
Fallowfield, Lesley; Moos, Roger von; Costa, Luis; Stopeck, Alison; Clemons, Mark; Clarke, Noel; Braun, Ada; Chung, Karen. "Weighing Bone-targeted Treatment Options for Patients with Solid Tumours and Skeletal Complications from Metastatic Disease". European Oncology & Haematology 08 03 (2012): 148. http://dx.doi.org/10.17925/eoh.2012.08.3.148.
Publicado • 10.17925/eoh.2012.08.3.148
Coleman R; Costa L; Saad F; Cook R; Hadji P; Terpos E; Garnero P; et al. "Consensus on the utility of bone markers in the malignant bone disease setting.". (2011): http://europepmc.org/abstract/med/21411334.
10.1016/j.critrevonc.2011.02.005
Ha NH; Nair VS; Reddy DN; Mudvari P; Ohshiro K; Ghanta KS; Pakala SB; et al. "Lactoferrin-endothelin-1 axis contributes to the development and invasiveness of triple-negative breast cancer phenotypes.". (2011): http://europepmc.org/abstract/med/22006997.
10.1158/0008-5472.CAN-11-1143
Félix, J.; Andreozzi, V.; Soares, M.; Borrego, P.; Gervásio, H.; Moreira, A.; Costa, L.; et al. "Hospital Resource Utilization and Treatment Cost of Skeletal-Related Events in Patients with Metastatic Breast or Prostate Cancer: Estimation for the Portuguese National Health System". Value in Health 14 4 (2011): 499-505. http://dx.doi.org/10.1016/j.jval.2010.11.014.
Publicado • 10.1016/j.jval.2010.11.014
Richardson, G. E.; Ciuleanu, T. E.; Costa, L.; Gans, S. J. M.; Garcia Saenz, J. Á.; Hirsh, V.; Hungria, V.; et al. "Denosumab versus zoledronic acid in patients with bone metastases from solid tumors other than breast and prostate cancers or multiple myeloma: A number needed to treat (NNT) analysis.". Journal of Clinical Oncology 29 15_suppl (2011): 9115-9115. http://dx.doi.org/10.1200/jco.2011.29.15_suppl.9115.
Publicado • 10.1200/jco.2011.29.15_suppl.9115
Henry DH; Costa L; Goldwasser F; Hirsh V; Hungria V; Prausova J; Scagliotti GV; et al. "Randomized, double-blind study of denosumab versus zoledronic acid in the treatment of bone metastases in patients with advanced cancer (excluding breast and prostate cancer) or multiple myeloma.". (2011): http://europepmc.org/abstract/med/21343556.
10.1200/JCO.2010.31.3304
Costa L; Harper P; Coleman RE; Lipton A. "Anticancer evidence for zoledronic acid across the cancer continuum.". (2011): http://europepmc.org/abstract/med/21353179.
10.1016/S1040-8428(11)70006-3
Costa, L.; Luís*, I.; Alho, I.; Fernandes, A.; Casimiro, S.; Lee, B.H.; Gangolli, E.A.; et al. "Expression of matrix metalloproteinase 1 (MMP1) and dickkopf-1 (DKK1) in bone metastatic tissue (BMT) and in serum of patients with bone metastases (BM) from different solid tumors". Bone 48 1 (2011): S25-S26. http://dx.doi.org/10.1016/j.bone.2010.10.068.
Publicado • 10.1016/j.bone.2010.10.068
Lipton A; Costa L; Coleman RE. "Bone turnover markers: tools for prognosis and monitoring response to bisphosphonates?". (2011): http://europepmc.org/abstract/med/22142664.
10.3233/BD-2010-0327
Brown JE; Cook RJ; Lipton A; Costa L; Coleman RE. "Prognostic factors for skeletal complications from metastatic bone disease in breast cancer.". (2010): http://europepmc.org/abstract/med/20574672.
10.1007/s10549-010-0981-1
Candeias, C. M.; Luis, I.; Ribeiro, J.; Costa, L.; de Almeida, L. S.; Gomes, M. M.; Barreto, L.; Brito-Avo, L.; Ducla-Soares, J. L.. "Extended remission of metastatic epithelioid angiosarcoma of the heart with liposomal doxorubicin". Case Reports 2010 feb19 1 (2010): bcr0820092157-bcr0820092157. http://dx.doi.org/10.1136/bcr.08.2009.2157.
Publicado • 10.1136/bcr.08.2009.2157
Lipton A; Campbell-Baird C; Harvey H; Kim C; Demers L; Costa L. "Phase I trial of zoledronic acid + imatinib mesylate (Gleevec) in patients with bone metastases.". (2010): http://europepmc.org/abstract/med/19652577.
10.1097/COC.0b013e31819cccdc
Aapro M; Saad F; Costa L. "Optimizing clinical benefits of bisphosphonates in cancer patients with bone metastases.". (2010): http://europepmc.org/abstract/med/21051658.
10.1634/theoncologist.2007-0245
Luís, I.V.; Casimiro, S.; Ribeiro, J.; Costa, L.. "Zoledronic acid: Its use in the treatment of breast cancer". Clinical Medicine Insights: Therapeutics 2 (2010): 913-926. http://www.scopus.com/inward/record.url?eid=2-s2.0-78650793004&partnerID=MN8TOARS.
10.4137/CMT.S2353
Fitch M; Maxwell C; Ryan C; Löthman H; Drudge-Coates L; Costa L. "Bone metastases from advanced cancers: clinical implications and treatment options.". (2009): http://europepmc.org/abstract/med/19948468.
10.1188/09.CJON.701-710
Alves, Ana Rafaela; Costa, Luis; Ferreira, Ana; Ventura, Madeira; Riscado, Vaz. "P0769 PRIMARY LEFT PSOAS ABSCESS: AN UNUSUAL CASE REPORT". European Journal of Internal Medicine 20 (2009): S250-S251. http://dx.doi.org/10.1016/s0953-6205(09)60788-3.
Publicado • 10.1016/s0953-6205(09)60788-3
Costa L; Major PP; Costa, Luis; Major, Pierre P. "Effect of bisphosphonates on pain and quality of life in patients with bone metastases.". Nature Reviews Clinical Oncology 6 3 (2009): 163-174. http://europepmc.org/abstract/med/19190592.
10.1038/ncponc1323
Casimiro, S.; Guise, T.A.; Chirgwin, J.. "The critical role of the bone microenvironment in cancer metastases". Molecular and Cellular Endocrinology 310 1-2 (2009): 71-81. http://www.scopus.com/inward/record.url?eid=2-s2.0-69249206543&partnerID=MN8TOARS.
10.1016/j.mce.2009.07.004
Vitor, R.F.; Esteves, T.; Marques, F.; Raposinho, P.; Paulo, A.; Rodrigues, S.; Rueff, J.; et al. "99mTc-Tricarbonyl Complexes Functionalized with Anthracenyl Fragments: Synthesis, Characterization, and Evaluation of Their Radiotoxic Effects in Murine Melanoma Cells". Cancer Biotherapy and Radiopharmaceuticals 24 5 (2009): 551-563. http://www.scopus.com/inward/record.url?eid=2-s2.0-70449113426&partnerID=MN8TOARS.
10.1089/cbr.2009.0647
Costa, Luis; Badia, Xavier; Chow, Edward; Lipton, Allan; Wardley, Andrew. "Impact of skeletal complications on patients’ quality of life, mobility, and functional independence". Supportive Care in Cancer 16 8 (2008): 879-889. http://dx.doi.org/10.1007/s00520-008-0418-0.
Publicado • 10.1007/s00520-008-0418-0
Ribeiro, J.; Luis, I.; Fortunato, M.; Correia, L.; Quintela, A.; Cortes, P.; Costa, L.. "Fulvestrant in metastatic breast cancer previously treated with aromatase inhibitors". European Journal of Cancer Supplements 6 7 (2008): 180. http://dx.doi.org/10.1016/s1359-6349(08)70751-1.
Publicado • 10.1016/s1359-6349(08)70751-1
Aapro, M.; Abrahamsson, P.A.; Body, J.J.; Coleman, R.E.; Colomer, R.; Costa, L.; Crinò, L.; et al. "Guidance on the use of bisphosphonates in solid tumours: recommendations of an international expert panel". Annals of Oncology 19 3 (2008): 420-432. http://dx.doi.org/10.1093/annonc/mdm442.
Publicado • 10.1093/annonc/mdm442
Alho, I.; Clara Bicho, M.; Carvalho, R.; da Silva, A.P.; Costa, L.; Bicho, M.. "Low molecular weight protein tyrosine phosphatase genetic polymorphism and susceptibility to cancer development". Cancer Genetics and Cytogenetics 181 1 (2008): 20-24. http://dx.doi.org/10.1016/j.cancergencyto.2007.11.004.
Publicado • 10.1016/j.cancergencyto.2007.11.004
Casimiro, Sandra; Alho, Irina; Fernandes, Afonso; Lipton, Allan; Guise, Theresa; Costa, Luis. "P38. RANKL plays a role in migration and invasion of the bone-seeking cell line MDA-MB-231-BO2 and regulates MMP1 and MMP9 expression". Cancer Treatment Reviews 34 (2008): 27-28. http://dx.doi.org/10.1016/j.ctrv.2008.03.080.
Publicado • 10.1016/j.ctrv.2008.03.080
Costa, L.. "Bisphosphonates: Reducing the risk of skeletal complications from bone metastasis". The Breast 16 (2007): 16-20. http://dx.doi.org/10.1016/j.breast.2007.10.005.
Publicado • 10.1016/j.breast.2007.10.005
Felix, J.; Andreozzi, V.; Soares, M.; Gervásio, H.; Moreira, A.; Costa, L.; Peralta, F.; et al. "Direct hospital costs of skeletal-related events (SRE) in Portuguese patients (pts) with breast cancer (BC) and bone metastases". Journal of Clinical Oncology 25 18_suppl (2007): 17084-17084. http://dx.doi.org/10.1200/jco.2007.25.18_suppl.17084.
Publicado • 10.1200/jco.2007.25.18_suppl.17084
Costa, Luis; Lipton, Allan; Coleman, Robert E.; Costa L; Lipton A; Coleman RE. "Role of Bisphosphonates for the Management of Skeletal Complications and Bone Pain from Skeletal Metastases". Supportive Cancer Therapy 3 3 (2006): 143-153. http://dx.doi.org/10.3816/sct.2006.n.012.
10.3816/sct.2006.n.012
Casimiro, S.; Tenreiro, R.; Monteiro, A.A.. "Identification of pathogenesis-related ESTs in the crucifer downy mildew oomycete Hyaloperonospora parasitica by high-throughput differential display analysis of distinct phenotypic interactions with Brassica oleracea". Journal of Microbiological Methods 66 3 (2006): 466-478. http://www.scopus.com/inward/record.url?eid=2-s2.0-33746168643&partnerID=MN8TOARS.
10.1016/j.mimet.2006.01.015
Casimiro, S.; Moura, M.; Zé-Zé, L.; Tenreiro, R.; Monteiro, A.A.. "Internal transcribed spacer 2 amplicon as a molecular marker for identification of Peronospora parasitica (crucifer downy mildew)". Journal of Applied Microbiology 96 3 (2004): 579-587. http://www.scopus.com/inward/record.url?eid=2-s2.0-1542299157&partnerID=MN8TOARS.
10.1111/j.1365-2672.2004.02193.x
Demers LM; Costa L; Lipton A. "Biochemical markers and skeletal metastases.". (2003): http://europepmc.org/abstract/med/14600604.
Demers, Laurence M.; Costa, Luis; Lipton, Allan. "Biochemical Markers and Skeletal Metastases". Clinical Orthopaedics and Related Research 415 (2003): S138-S147. http://dx.doi.org/10.1097/01.blo0000092979.12414.54.
10.1097/01.blo0000092979.12414.54
Costa L; Demers LM; Gouveia-Oliveira A; Schaller J; Costa EB; de Moura MC; Lipton A. "Prospective evaluation of the peptide-bound collagen type I cross-links N-telopeptide and C-telopeptide in predicting bone metastases status.". (2002): http://europepmc.org/abstract/med/11821470.
Ali, S. M.; Esteva, F. J.; Hortobagyi, G.; Harvey, H.; Seaman, J.; Knight, R.; Costa, L.; Lipton, A.. "Safety and Efficacy of Bisphosphonates Beyond 24 Months in Cancer Patients". Journal of Clinical Oncology 19 14 (2001): 3434-3437. http://dx.doi.org/10.1200/jco.2001.19.14.3434.
10.1200/jco.2001.19.14.3434
Lipton, A.; Costa, L.; Ali, S.M.; Demers, L.M.. "Bone markers in the management of metastatic bone disease". Cancer Treatment Reviews 27 3 (2001): 181-185. http://dx.doi.org/10.1053/ctrv.2000.0212.
10.1053/ctrv.2000.0212
Tamada, Tsutomu; Sone, Teruki; Tomomitsu, Tatsushi; Jo, Yoshimasa; Tanaka, Hiroyoshi; Fukunaga, Masao. "Biochemical markers for the detection of bone metastasis in patients with prostate cancer: diagnostic efficacy and the effect of hormonal therapy". Journal of Bone and Mineral Metabolism 19 1 (2001): 45-51. http://dx.doi.org/10.1007/s007740170059.
10.1007/s007740170059
Mandal, Mahitosh; Vadlamudi, Ratna; Nguyen, Diep; Wang, Rui-An; Costa, Luis; Bagheri-Yarmand, Rozita; Mendelsohn, John; Kumar, Rakesh. "Growth Factors Regulate Heterogeneous Nuclear Ribonucleoprotein K Expression and Function". Journal of Biological Chemistry 276 13 (2000): 9699-9704. http://dx.doi.org/10.1074/jbc.m008514200.
10.1074/jbc.m008514200
Demers, Laurence M.; Costa, Luis; Lipton, Allan. "Biochemical markers and skeletal metastases". Cancer 88 S12 (2000): 2919-2926. http://dx.doi.org/10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z.
10.1002/1097-0142(20000615)88:12+<2919::aid-cncr7>3.0.co;2-z
M. Costa, Luis A.; Kopreski, Michael S.; Demers, Laurence M.; Chinchilli, Vernon M.; Santen, Richard J.; Harvey, Harold A.; Lipton, Allan. "Effect of the potent aromatase inhibitor fadrozole hydrochloride (CGS 16949A) in postmenopausal women with breast carcinoma". Cancer 85 1 (1999): 100-103. http://dx.doi.org/10.1002/(sici)1097-0142(19990101)85:1<100::aid-cncr14>3.0.co;2-5.
10.1002/(sici)1097-0142(19990101)85:1<100::aid-cncr14>3.0.co;2-5
Lipton, A.; Demers, L.; Curley, E.; Chinchilli, V.; Gaydos, L.; Hortobagyi, G.; Theriault, R.; et al. "Markers of bone resorption in patients treated with pamidronate". European Journal of Cancer 34 13 (1998): 2021-2026. http://dx.doi.org/10.1016/s0959-8049(98)00277-9.
10.1016/s0959-8049(98)00277-9
Curley, E.; Demers, L.; Costa, L.; Chinchilli, V.; Seaman, J.; Reitsma, D.; Knight, R.; Lipton, A.. "Monitoring treatment of bone metastases". European Journal of Cancer 33 (1997): S148-S149. http://dx.doi.org/10.1016/s0959-8049(97)85240-9.
10.1016/s0959-8049(97)85240-9

Capítulo de livro

Kumar, Rakesh; George, Bijesh; Campbell, Marcia R.; Verma, Nandini; Paul, Aswathy Mary; Melo-Alvim, Cecília; Ribeiro, Leonor; et al. "HER family in cancer progression: From discovery to 2020 and beyond". In Advances in Cancer Research, 109-160. Elsevier, 2020.
10.1016/bs.acr.2020.04.001
Martins, Marta; Mansinho, André; Cruz-Duarte, Raquel; Martins, Soraia Lobo; Costa, Luís. "Anti-EGFR Therapy to Treat Metastatic Colorectal Cancer: Not for All". In Targeted Therapy of Colorectal Cancer Subtypes, 113-131. Springer International Publishing, 2018.
Publicado • 10.1007/978-3-030-02771-1_8
Mansinho, André; Macedo, Daniela; Fernandes, Isabel; Costa, Luís. "Castration-Resistant Prostate Cancer: Mechanisms, Targets and Treatment". In Molecular & Diagnostic Imaging in Prostate Cancer, 117-133. Springer International Publishing, 2018.
Publicado • 10.1007/978-3-319-99286-0_7
Ferreira, Arlindo R.; Abrunhosa-Branquinho, André; Jorge, Marília; Costa, Luís; Vaz-Luís, Inês. "Bone Metastases". In International Manual of Oncology Practice, 867-889. Springer International Publishing, 2015.
Publicado • 10.1007/978-3-319-21683-6_40
Lipton, Allan; Costa, Luis; Sieber, Paul; Dougall, William C.; Braun, Ada. "New Targeted Therapies for Bone Metastases". In Cancer Metastasis - Biology and Treatment, 235-246. Springer Netherlands, 2013.
Publicado • 10.1007/978-94-007-7569-5_12

Atividades

Apresentação oral de trabalho

	Título da apresentação	Nome do evento Anfitrião (Local do evento)
2020/02/14	Adjuvant antiresorptive therapy for early breast cancer. Where are we?	Innovation Breast Cancer (Madrid, Espanha)
2019/12/13	Tumor Microenvironment: “Back to Medicine”	Dev BioMed Symposium
2019/09/13	Immuno-Oncology in Other Solid Tumors	I ASEICA-ASPIC International Meeting
2019/05/09	Cancer and Education	European Association for Cancer Education-32nd Annual Scientific Meeting
2019/05/02	Impact of Innovation in Patients and Society	Science and Innovation Congress Switzerland - Portugal
2019/03/01	Breast cancer and the bone: recent studies	Innovation Breast Cancer (Madrid, Espanha)
2018/11/22	Sociedade Portuguesa de Oncologia: Clinica e Investigação em Oncologia	Sociedade Portuguesa de Oncologia: Clinica e Investigação em Oncologia
2018/11/15	Conferência LPCC-Coimbra
2018/11/09	CDK inhibitors in Breast Cancer	Oncologia D’OR (Rio de Janeira, Brasil)
2018/10/17	O futuro da situação oncológica: o que se prevê e o que não se prevê. Situação Oncológica: abordagem multidisciplinar	Infarmed e Associação Portuguesa de Ciências da Saúde e do Comportamento
2018/10/13	Como optimizar o tratamento do cancro da mama avançado HER2+	Sociedade Portuguesa de Senologia
2018/06/21	Tumor microenvironment in cancer progression	2nd Onco Emergence Forum
2018/06/14	Targeting the microenvironment of solid tumors: Clinical achievements and challenges	8th International Conference on Tumor Microenvironment, Progression, Therapy & Prevention
2017/10/25	Personalized Medicine in Cancer: Aims and Challenges for Portugal	European Commission (Brussels, Bélgica)
2017/10/13	Bone-targeted therapies in Prostate cancer: updating the landscape	Multidisciplinary Genitourinary Oncology Course
2017/05	Bone Health in Curable Breast Cancer	Leaping Forward Meeting
2017/05	Liquid Biopsies in Clinical Oncology: How many dimensions and how much dynamics	24th Cancer Porto Meeting
2017/05	Breast Cancer Diagnosis and Treatment: Still on the Road to improve Results	3rd ESOP-ESO Advanced Master Class in Oncology Pharmacy
2017/04	Cancer Research: A Selection of “Hot Spots”	Instituto Português de Oncologia- Portuguese League Against Cancer
2017/03	New drug toxicity	ESMO Update for Practising Oncologists
2016/06	Blood markers as endpoints, Inclusion of Breast Cancer Patients with Bone-only Metastasis in Clinical Trials Consensus Development Meeting	ASCO-FDA Meeting (chicago, Estados Unidos)
2016/05	Breast Cancer And Bone Metastasis – Do We Still Have A Problem?	CABS-ECTS (Rome, Itália)
2016/04	Cancer and metastases: is bone a useful paradigm?	INSERM UMR 1033 (Lyon, França)
2016/02	Nanomedicine in Cancer: what we can offer so far	NWCD16, INL - International Iberian Nanotechnology Laboratory
2015/11	Prognostic Biomarkers in Metastatic Breast Cancer	Cancer Genomics and Biology 2015 (China)
2015/10	Molecular Mechanisms in metastases in breast cancer-is bone a useful paradigm?	Annual Breast Cancer Conference
2015/09	Mechanisms of Resistance in Breast Cancer	UMIB-SUMMIT
2015/04	New therapies and approaches in cancer-induced bone disease. Clinical debate: Radium-223 can augment the efficacy of cancer and bone treatments for metabolic bone disease	ECTS & IBMS Joint Meeting (Países Baixos)
2015/04	Current & Novel Therapies for Bone Metastases - Moving away from bone-targeted agents? Current agents, indicators of response, sensitivity and resistance	2014 Bonus 9 Meeting (Canadá)
2015/04	Re-visiting the vicious cycle in bone metastases: Host Variability and Oncodynamics	Ottawa Hospital Research Institute Seminar (Canadá)
2014/11	Cancer Metastases: is bone a useful paradigm?	1st ASPIC International Congress
2014/06	An update in the management of bone metastases in patients with solid tumours: overview of the clinical data and practicalities of management	Healthcare Professionals at the Royal College of Obstetricians and Gynecologists
2014/05	The current status of treatment of cancer-related bone disease	Haukeland University Hospital (Noruega)
2014/02	Treatment of bone metastases from breast cancer, Innovation in Breast Cancer	IBC 2014 (Espanha)
2013/09	Difficulties in Pharmacogenomics Clinical Studies in Cancer	3rd ESPT Pharmacogenomics Advanced Training Course
2013/09	Oncologic treatment of tumors with disorders of the ALK gene	European Congress of Pathology
2013/04	Improving the medical management of bone metastases, Challenging Metastatic Cancer: Remodeling Management - Evolution or Revolution	Royal College of Physicians, London – Kesington Forum
2013/03	Management of Bone Metastases	institutional seminar at St. Vicent’s Univeristy Hospital (Irlanda)
2012/09	Accelerating drug discovery: form bench to bedside, Young Master Class	37th ESMO congress (Áustria)
2012/09	A new era in skeletal health for patients with solid tumors, The science behind the success	3rd International Lung Cancer Seminar (Grécia)
2012/05	Bone-Targeted therapies in Bone Metastases: clinical impact and expectations	Grand Rounds of Hematology & Oncology (Canadá)
2012/05	Clinical Impact of Bone-Targeted Therapies in Patients with Bone Metastases	Grand Rounds of Oncology, Cancer Care Manitoba (Canadá)
2012/04	mTOR pathway: a common target in cancer or just a co-target ?	XXI Porto Cancer Meeting
2011/02	Established Benefits of Bisphosphonates in Early Breast Cancer	Special Lecture, 8th Kyushu Regional Meeting of the Japanese Breast Cancer Society (Japão)
2011/01	Clinical Impact of Bone-Targeted Therapies in Cancer	institutional seminar at Gregorio Marañon Hospital (Espanha)
2011	Molecular Therapy in Breast Cancer with Bone Metastases	1st Global Cancer Genomics Consortium TMC Symposium: the interface between genomics and cancer medicine (Índia)
2008/09	Optimizing bisphosphonate therapy in breast and prostate cancers: How to better prevent bone complication? ,	Oncology Grand Rounds (Canadá)
2008/03	Adjuvant Hormonal Treatment of Breast Cancer	20th European Congress of Obstetrics and Gynecology
2007/05	Maintaining patient autonomy: management of metastatic disease	3rd Educational Breast Care Meeting (Espanha)
2006/09	Bone Metastasis: Preserving Patient Functional Independence	European Society of Medical Oncology (Turquia)
2006/09	The Role of RANK Ligand in Cancer-induced Bone Disease	Expanding Therapeutic Options in Oncology, (Áustria)
2005/07	Coosing the Optimum Treatment for Bone Complications	7th MASCC (Multinational Association of Supportive Care in Cancer) (Suiça)
2005/06	The Role of Bisphosphonates in Breast Cancer	2nd Central European Cooperative Oncology Group (Áustria)
2004/12	Parathyroid Hormone-related Protein (PTHrP) in Breast Cancer Metastasis	institutional seminar at M.D. Anderson Cancer Center (Estados Unidos)
2004/04	Endocrine Therapy in Breast Cancer: Clinical Aspects	XIV Porto Cancer Meeting
2003/12	What do Bone Markers tell us about Clinical Status and Pathophysiology in Bone Metastases?	M.D. Anderson Cancer Center

Orientação

	Título / Tema Papel desempenhado	Curso (Tipo) Instituição / Organização
2019 - Atual	O Espectro Metastático: Oligometástases vs Polimetástases Orientador
2018 - Atual	RANK-pathway as a mediator of resistance to cyclin inhibitors and HER2-targeted therapies in breast cancer Coorientador
2018 - Atual	Phospholipase C Signalling in Resistance to Anti-RTK Therapy Coorientador
2017 - Atual	An MMP-9 inhibitory protein isolated from Lupinus albus seeds in colon adenocarcinoma development Coorientador
2016 - Atual	Patterns of Care and Comparative Effectiveness of Endocrine Therapy for Breast Cancer Orientador
2017 - 2019	Exploring genomic copy number variation analysis to stratify recurrence risk of early-stage breast carcinoma Orientador
2016 - 2019	Pesquisa de alterações moleculares ao nível do DNA de doentes com cancro da mama estadio IV Orientador
2016 - 2017	Immunogenicity of colorectal cancer with microsatellite instability Orientador
2012 - 2017	Time trends of treatment and outcomes in women with T1 node negative breast cancer Orientador
2014 - 2015	The influence of menopausal status on bone turnover and disease control in breast cancer patients with metastatic bone disease treated with chemotherapy plus zoledronic acid: an exploratory retrospective cohort study Orientador
2011 - 2015	Effects of chemotherapy and radiotherapy in rectal cancer: significance of different cellular outcomes in tumour behavior Orientador
2009 - 2013	The importance of Low Molecular Weight Protein Tyrosine Phosphatase in the progression of metastatic bone disease and therapeutic reponse Orientador
2006 - 2007	Competências dos enfermeiros para cuidar do coente em cuidados paliativos Orientador
2006 - 2007	Cuidar do doente terminal em ensino clinico - o desenvolvimento de competências Orientador
2006 - 2007	Classificação de doentes com cancro, em categorias de risco, no desenvolvimento de complicações em metástases ósseas Coorientador
2005 - 2007	Ultrasound Contrast Agents for in situ Drug Delivery Coorientador
2005 - 2006	Dor total nos Doentes com Metastização Óssea Orientador

Júri de grau académico

	Tema Tipo de participação	Nome do candidato (Tipo de grau) Instituição / Organização
2017	Analysis of the effect of the over-expression of receptor activator of NF-¿B (RANK) in estrogen receptor-positive breast cancer cells over tumour behaviour in vivo	Inês Correia (Mestrado)
2017	Role of PLC¿1 in the Resistance Mechanism to Anti-EGFR Therapy in Metastatic Colorectal Cancer	Raquel Duarte (Mestrado)
2017	The DNA damage response in terminally differentiated skeletal myotubes	Ana Duarte (Mestrado)
2016	Strategic Management of New Drugs in Oncology – The Importance of an Ethical and Interdisciplinar Framework	Isabel Borges da Costa (Doutoramento)
2015	Analysis of outcome and cancer stem cells status in patients with resectable pancreatic adenocarcinoma	Daniela Dias-Santos (Doutoramento)
2015	Neurological Complication of Breast Cancer	Susana Filipa Pereira (Doutoramento)
2015	Células Estaminais do Cancro do Endométrio: Caracterização, resposta à terapêutica e padrão de metastização in vivo	Maria João Leal Carvalho (Doutoramento)
2015	Prospective analysis of regulatory T cell homeostasis after allogeneic hematopoietic stem cell transplantation	Ana Isabel da Silva Vieira (Mestrado)
2015	Low doses of ionizing radiation induce angiogenesis after radiotherapy	Carolina Isabel Garcia Cardina (Mestrado)
2015	Luminal-type breast cancer: prognostic value of RANK-positive lymphatic nodes RANK+ luminal breast cancer in vitro approach	Sara Santos Henriques (Mestrado)
2015	Synthesis, characterization and biological assessment of multi-functional bone-seeking agents. Evalution of the effects of new compounds in breast and prostate cancer cell lines, cell outcome and assessment of the mechanisms of action	Diana Domingos de Matos (Mestrado)
2015	Qualidade de Vida em Doentes com Metastases Ósseas: Validação da Escala EOTC QLQ BM22	Ana Mafalda Mendes (Mestrado)
2015	Male breast cancer: Prognostic and predictive factors of response to therapy	Antonio Miguel Henriques da Cunha Abreu (Doutoramento)
2014	The role of systemic metabolism in breast cancer progression	Catarina Sofia Granja da Fonseca (Doutoramento)
2014	Proteomic Characterization of Lung Cancer and Chronic Obstrutive Pulonary Disease: A bronchoalveolar lavage fluid analysis	Ana Barbosa Nogal (Doutoramento)
2014	Importância clínica de novos marcadores moleculares no cancro colorectal,	Maria Amélia Pereira (Doutoramento)
2011	Avaliação functional de resistência a múltiplos fármacos em tumores sólidos: modelos in vitro e in vivo	Célia Maria Freitas Gomes (Doutoramento)
2011	The Role of the DELTA-LIKE 4 NOTCH Ligand in Tumor Angiogenesis	Dusan Djokovic (Doutoramento)
2010	Tradução e adaptação linguistica e cultural para português do Liverpool Care Pathway	Maria Flávia Silva e Sousa (Mestrado)
2010	Acuidade prognóstica em fim de vida – valor preditivo de quatro métodos na estimativa de sobrevivência de doentes oncológicos de um hospital central e universitário português	Filipa Gonçalves Tavares (Mestrado)
2009	Qualidade de vida dos doentes terminais oncológicos em internamento e em ambulatório	Lucinda Maria da Silva Marques (Mestrado)
2007	Alterações genéticas associadas ao processo de carcinogénese do tumor de origem folicular na glândula tiroideia	Raquel Ferreira Rodrigues (Doutoramento)
2007	Validação de uma escala de satisfação de doentes	Maria Georgiana Gama (Mestrado)
2007	Human Topoisomerase Iia in Chromatin based phenomena	Marta Elisa Dias Agostinho (Doutoramento)
2006	Bone Marrow as Sanctuary for Breast Cancer Cells: Identification of New Targets for Therapeutic Intervention in Micrometastatic Disease	Joana G. Brandão (Doutoramento)
2005	Abordagem psicossomática da ansiedade e depressão em doentes oncológicos – Estudo Epidemiológico	Ana Cristina Charraz (Mestrado)
2005	Falência dos Mecanismos de Regulação Endócrina na Obesidade e sua relação com a Carcinogénese Mamária	Ana Paula Soares Santos (Mestrado)
2005	Tumores Mamários da Cadela	Sandra Manuela Serrano (Doutoramento)
2005	Estudo das Alterações Genéticas envolvidas na via da Carcinogénese do Cancro do Cólon e Recto associada à Colite Ulcerosa	Lara Cristina Sayanda (Doutoramento)
2005	Ética da Gestão de Recursos em Geriartria	Olívia Rego Tavares (Mestrado)
2005	A necessidade de uma Unidade de Cuidados Paliativos no Distrito de Santarém	Emanuela Santos Andrade (Mestrado)
2005	A Medicina Geral e Familiar e o Luto	Maria de Fátima Azevedo (Mestrado)
2004	Avaliação do Her-2 em carcinomas invasivos da mama: correlação entre estudo imunohistoquímico e hibridização in situ por fluorescência	Maria Fernanda Milanezi (Mestrado)
2004	O cuidador e o doente paliativo no Alto Minho	Maria Amorim Cerqueira (Mestrado)

Arbitragem científica em conferência

	Nome da conferência	Local da conferência
2020 - 2020	Co-Chair, EACR-AACR-ASPIC meeting
2016 - 2016	Metastatic Breast Cancer, ESMO Meeting
2012 - 2012	12th International CIBD Meeting

Arbitragem científica em revista

	Nome da revista (ISSN)	Editora
2019 - Atual	PLoS ONE (1932-6203)	Public Library of Science
2018 - Atual	ecancermedicalscience (1754-6605)	Ecancer Global Foundation
2016 - Atual	Journal of Bone Oncology (2212-1374)	Elsevier
2017 - 2018	The Lancet Oncology (1470-2045)	Elsevier
2016 - 2017	Drugs (1179-1950)	Springer-Verlag
2015 - 2017	British Journal of Cancer (1532-1827)	Springer Science and Business Media LLC
2015 - 2017	The Lancet (1474-547X)	Elsevier
2015 - 2017	Oncotarget (1949-2553)	"Impact Journals, LLC "
2014 - 2016	Cancer Treatment Reviews (0305-7372)	Elsevier
2014 - 2016	Therapeutic Advances in Medical Oncology (1758-8359)	SAGE Publications
2014 - 2016	The Breast (0960-9776)	Elsevier
2012 - 2016	Cancer Letters (0304-3835)	Elsevier
2013 - 2015	Breast Cancer Research and Treatment (1573-7217)	Springer-Verlag
2012 - 2014	European Journal of Molecular Cancer	Science Repository OU
2012 - 2014	The Oncologist (1549-490X)	Alphamed Press
2012 - 2014	Oncogene (0950-9232)	Springer Science and Business Media LLC
2011 - 2013	Bone (8756-3282)	Elsevier
2011 - 2013	Critical Reviews in Oncology/Hematology (1040-8428)	Elsevier
2011 - 2011	Annals of Oncology (1569-8041)	Elsevier

Consultoria / Parecer

	Descrição da atividade	Instituição / Organização
2015 - Atual	Expert Reviewer for Funding and Grants	European Research Council, Bélgica
2015 - Atual	Expert reviewer for funding and grants	Fundo iMM-Laço, Portugal
2014 - Atual	Expert reviewer for funding and grants	Cancer Research UK, Reino Unido
2014 - Atual	Expert reviewer for funding and grants	CAIBER Spanish Clinical Research Network, Espanha
2014 - Atual	Expert reviewer for funding and grants	Institut National du Cancer, França
2013 - Atual	Expert reviewer for funding and grants	INSERM, França
2012 - Atual	Expert reviewer for funding and grants	Innovational Research Incentives Scheme Vidi, Países Baixos
2011 - Atual	Expert reviewer for funding and grants	Fundação para a Ciência e a Tecnologia, Portugal
2007 - Atual	Expert reviewer for funding and grants	Liga Portuguesa Contra o Cancro, Portugal
2005 - 2005	Consultant in Medical Oncology	Hospital Prof. Doutor Fernando Fonseca E.P.E, Portugal
2004 - 2004	Consultant in Medical Oncology Curriculum Evaluation	Direcção-Geral da Saúde, Portugal

Membro de associação

	Nome da associação	Tipo de participação
2018 - Atual	Board of Oncology at the National College of Medicine	President
2013 - Atual	American Society of Medical Oncology (ASCO)	Member
2013 - Atual	European Society of Medical Oncology (ESMO)	Member
2013 - Atual	European Association for Cancer Research (EACR)	Member
2001 - Atual	Portuguese Board of Internal Medicine	Member
2001 - Atual	Portuguese Board of Medical Oncology	Member
2016 - 2020	Portuguese Association of Cancer Research (ASPIC)	President
2003 - 2005	Portuguese Society of Oncology	Direction Committee

Membro de comissão

	Descrição da atividade Tipo de participação	Instituição / Organização
2016 - Atual	National Committee: Oncology Reference Centers	Governo da República Portuguesa, Portugal
2011 - 2016	Portuguese Head	Global Cancer Genomics Consortium, Portugal

Distinções

Título

2018	President of the Board of Oncology at the National College of Medicine
2016	President of Portuguese Association of Cancer Research (ASPIC)
2011	Portugal Representitive in Global Cancer Genomics Consortium
2007	Head of Translational Oncobiology Research Unit of Hospital de Santa Maria
2003	Direction committee of Portuguese Society of oncology